FDA grants breakthrough device designation to Diadem's AlzoSure predict prognostic blood test for the early prediction of Alzheimer's disease

Diadem

18 January 2022 - First prognostic blood test that can predict likely progression to Alzheimer's disease up to six years in advance.

Diadem today announced that the U.S. FDA has granted breakthrough device designation for AlzoSure Predict, Diadem's blood-based biomarker prognostic assay designed to identify with high accuracy whether individuals over the age of 50 with signs of cognitive impairment will or will not progress to Alzheimer's disease up to six years before definitive symptoms are apparent.

Read Diadem press release

Michael Wonder

Posted by:

Michael Wonder